Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Medtronic receives CE Mark for next-generation TAVI system

Medtronic receives CE Mark for next-generation TAVI system

9th September 2014

Medtronic has been granted European CE Mark approval for its new 23 mm CoreValve Evolut R System, for use in transcatheter aortic valve implantation (TAVI) applications.

The novel, self-expanding valve and 14FR equivalent delivery system offers new capabilities that  help to advance valve performance and deliverability during procedures, while also allowing users to recapture and reposition the valve during the deployment phase.

Consisting of the CoreValve Evolut R transcatheter aortic valve and EnVeo R Delivery Catheter System, the platform is designed for first-time positioning accuracy. It also offers a new InLine Sheath that significantly reduces its profile.

The launch will build upon the previous success of the CoreValve System, which has accumulated more than 65,000 implants worldwide to date.

Rhonda Robb, vice-president and general manager for heart-valve therapies at Medtronic, said: "A truly next-generation device, CoreValve Evolut R provides heart teams with meaningful advancements that will increase the potential for optimal device placement."

Last month, the company commenced the largest ever global trial of cardiac resynchronisation therapy in order to investigate the clinical advantages of its AdaptivCRT technology.ADNFCR-8000103-ID-801747519-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.